Skip to main content

Table 4 Selected relevant pre-clinical assays based on novel drug-loaded polymeric nanoparticles for the treatment of bacterial gastrointestinal infections

From: State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections

Bacteria Loaded molecule Polymeric matrix Surface modifications Dose Admin. route In vitro/In vivo model Results Ref
Helicobacter pylori CLR PLGA AGS cells/PEG 200 μL Incubation H. pylori Sydney strain 1 CLR-loaded AGS-NPs demonstrate
higer efficacy when compared with the free drug as well as a non-targeted NPs
Angsantikul et al. [91]
30 mg/kg O.g C57BL/6 mice
Vibrio cholerae PLGA GM1 / PEG 1 mg/mL Incubation V.cholerae N16961
ATCC cells
GM1-NPs show to function as toxin decoys by selectively and stably binding cholera toxin, and neutralizing its actions on epithelial cells in vitro and in vivo Das et al. [84]
250 μg/mL Intestine exposure C57BL/6 mice
Mycobacterium marinum PLGA 5 μL of NPs Oral intubation Zebrafish NPs are rapidly taken up in the intestine and transported to the liver and spleen Lovmo et al. [93]
Campylobacter jejuni CpG ODN PLGA 5/25 µg of NPs Oral treatment Chickens The microbiota of CpG ODN-NPs-treated chickens exhibits higher microbial diversity and lower numbers of Campylobacter than untreated-chickens Taha-Abdelaziz et al. [85]
Salmonella typhimurium cryptdin Chitosan 10/15 μg of NPs O.G BALB/c mice Infected mice treated with NPs show 83% survivability and approximately 2 log unit reductions in the bacterial load in the tissues versus 100% mortality observed with the free peptide Rishi et al. [89]
  1. AGS cells plasma membranes of gastric epithelial cells, ATCC Human HCA7 colon cancer cells, CLR clarithromycin, CpG ODN CpG oligodeoxynucleotide, GM1 monosialotetrahexosylganglioside, HCQ Hydroxychloroquine